OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Petrylak on the Potential Use of Erdafitinib in Metastatic Urothelial Cancer

September 15th 2023

Daniel P. Petrylak, MD, discusses the potential uses for erdafitinib, highlighting key studies evaluating the use of the agent in patients with metastatic urothelial cancer.

Dr Usmani on Identifying High-Risk Patients With Multiple Myeloma

September 15th 2023

Saad Z. Usmani, MD, MBA, FACP, discusses methods for identifying patients with high-risk multiple myeloma and notable disease characteristics in this population.

Dr. Ferrajoli on the Benefits and Limitations of Frontline Fixed-Duration Therapy in CLL

September 15th 2023

Alessandra Ferrajoli, MD, discusses the benefits and limitations of utilizing fixed-duration therapy with monoclonal antibodies in the frontline setting for patients with chronic lymphocytic leukemia.

Dr. Strati on the Investigation of Immunotherapy Combinations in Lymphoma

September 15th 2023

Paolo Strati, MD, discusses several ongoing investigations aiming to improve upon current immunotherapy combinations, highlighting the introduction of novel regimens into the treatment landscape of follicular lymphoma.

Dr Chari on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma

September 14th 2023

Ajai Chari, MD, discusses the use of the CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in the treatment of patients with multiple myeloma.

Dr Phadke on the Benefit of Sacituzumab Govitecan in HR+/HER2– Breast Cancer

September 14th 2023

Sneha Phadke, DO, MPH, discusses the benefit associated with treatment consisting of the antibody drug conjugates sacituzumab govitecan in hormone receptor-positive/HER2-negative breast cancer.

Dr Sharifi on the Importance of ctDNA Testing in Breast Cancer

September 14th 2023

Marina Sharifi, MD, PhD, discusses the benefit of utilizing personalized and targeted therapy approaches in the treatment of patients with breast cancer.

​​Dr DiNardo on Alternative Triplet Regimens For Select Patients With AML

September 14th 2023

Courtney DiNardo, MD, MSCE, discusses triplets that serve as alternatives to standard-of-care approaches with azacitidine and venetoclax doublet therapy in select patients with acute myeloid leukemia.

Dr. Ansell on the Development of Potential Immune-Harnessing Therapeutics in Lymphoma

September 14th 2023

Stephen M. Ansell, MD, PhD, highlights several emerging therapeutics that have the potential to better harness the immune system in patients with lymphoma subtypes.

Dr Ravandi-Kashani on the FDA Approval of Luspatercept in MDS

September 13th 2023

Farhad Ravandi-Kashani, MD, discusses the FDA approval of luspatercept in myelodysplastic syndrome.

Dr Seymour on the Importance of Targeted Therapy in CLL

September 13th 2023

John Seymour, MBBS, FRACP, PhD, discusses the importance of targeted therapy in patients with chronic lymphocytic leukemia.

Dr Hwang on Unmet Needs Remaining in Nonmetastatic Prostate Cancer

September 13th 2023

Clara Hwang, MD, discusses unmet needs in patients with nonmetastatic prostate cancer who then progress on novel agents and develop metastatic disease.

Dr Chari on the Selection of BCMA-Targeted Therapies Within Multiple Myeloma

September 13th 2023

Ajai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.

Dr Westin on the Updated Treatment Paradigm in Second-Line LBCL

September 13th 2023

Jason R. Westin, MD, director, discusses how the approval of CAR T-cell therapies in the second-line setting has radically shifted preferred treatment approaches in relapsed/refractory large B-cell lymphoma.

Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin Shortages

September 13th 2023

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

Dr Mehmi on the Rationale for Investigating Fianlimab/Cemiplimab in Advanced Melanoma

September 12th 2023

Inderjit Mehmi, MD, medical oncologist, discusses the rationale for investigating the combination of fianlimab and cemiplimab in patients who have advanced melanoma with poor-risk features

Dr Phadke on Sequencing ADCs in HR+/HER2– Breast Cancer

September 12th 2023

Sneha Phadke, DO, MPH, discusses sequencing treatment with antibody drug conjugates in hormone receptor-positive/HER2-negative breast cancer, as well as questions remaining within this space.

Dr Garcia-Manero on the Investigation of Luspatercept in Transfusion-Dependent MDS

September 12th 2023

Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept vs epoetin alfa in patients with erythropoiesis-stimulating agent-naïve, lower-risk myelodysplastic syndromes and disease-related anemia who requires red blood cell transfusions.

Dr Fakih on the Significance of the PROSPECT Trial in Rectal Cancer

September 12th 2023

Marwan G. Fakih, MD, expands on long-term findings from the phase 2/3 PROSPECT trial and how these findings may influence the optimal use of nonoperative management strategies in locally advanced rectal cancer.

Dr Richardson on the Potential Significance of Mezigdomide in Relapsed/Refractory Multiple Myeloma

September 12th 2023

Paul G. Richardson, MD, discusses how the continued development of the novel agent mezigdomide could affect the treatment paradigm for patients who progressed on, and developed resistance to, other available BCMA-directed therapies.

NEXT PAGE
PREVIOUS PAGE